2022
An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study
Geisen C, Kjaer M, Fleck E, Skogen B, Armstrong R, Behrens F, Bhagwagar Z, Braeuninger S, Mortberg A, Olsen K, Gastón Schäfer S, Walter C, Seifried E, Wikman A, Kjeldsen-Kragh J, Koehm M. An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study. Journal Of Thrombosis And Haemostasis 2022, 21: 838-849. PMID: 36696185, DOI: 10.1016/j.jtha.2022.11.041.Peer-Reviewed Original ResearchConceptsFetal/Neonatal Alloimmune ThrombocytopeniaNeonatal alloimmune thrombocytopeniaHPA-1aAlloimmune thrombocytopeniaHuman platelet antigen 1aTreatment-emergent adverse eventsPlacebo 1 hourHPA-1a antibodiesFNAIT casesHyperimmune IgGPrimary endpointAdverse eventsFetus/Healthy menSingle doseAntigen 1aHLA-A2Concept studyCohort 1PlaceboFlow cytometryThrombocytopeniaPlateletsAdministrationWeeks
2002
Acute citalopram administration produces correlated increases in plasma and salivary cortisol
Bhagwagar Z, Hafizi S, Cowen P. Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology 2002, 163: 118-120. PMID: 12185409, DOI: 10.1007/s00213-002-1149-4.Peer-Reviewed Original ResearchConceptsSalivary cortisol levelsCortisol levelsSelective serotonin re-uptake inhibitorsSalivary cortisolSerotonin re-uptake inhibitorsAcute citalopram administrationRe-uptake inhibitorsCross-over designSalivary cortisol concentrationsCitalopram administrationIntravenous administrationCortisol releaseHealthy volunteersCortisol concentrationsSaliva cortisolCitalopramCortisolParallel increaseAdministrationCorrelated increaseAcceptable means